DÜSSELDORF, Germany--(BUSINESS WIRE)--Ventac Partners announces today that it has successfully facilitated the completion of Miacom Diagnostic’s management buyout from the German-Finnish investor Inveni Capital Oy. As of the end of January, 2013, the majority of the company is owned and controlled by its current management team. The successful transaction facilitated by Ventac Partners new Düsseldorf office continues the firm’s stellar track record of molding life science, technology companies into viable commercial entities. Miacom specializes in IVD tests for detecting acute systemic diseases, such as sepsis and pneumonia. The company, headquartered in Düsseldorf, Germany, was founded in 2006 with a promising core technology and a vision to apply it toward faster and better methods to identify pathogens and determine their resistance to antibiotics. Inveni Capital’s investment has funded the development and commercialization of the company’s initial molecular diagnostic product line currently sold in the European market.
